| Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. | |
| | |
MedLine Citation:
|
PMID: 10362194 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The purpose of this study was to investigate the significance of the possible negative interaction between aspirin and angiotensin-converting enzyme (ACE) inhibitors. BACKGROUND: Several provocative reports have recently suggested that aspirin is unsafe in patients with heart failure and has negative interaction with ACE inhibitors that might attenuate their beneficial effects upon survival. METHODS: We analyzed mortality data of 11,575 patients with coronary artery disease screened for the Bezafibrate Infarction Prevention trial. A total of 1,247 patients (11%) were treated with ACE inhibitors. Of them, 618 patients (50%) used aspirin. RESULTS: Five-year mortality was lower among patients on ACE inhibitors and aspirin than patients on ACE inhibitors without aspirin (19% vs. 27%; p < 0.001). After adjusting for confounders, treatment with aspirin and ACE inhibitors remained associated with lower mortality risk than using ACE inhibitors only (relative risk [RR] = 0.71; 95% confidence interval [CI] = 0.56 to 0.91). Subgroup analysis of 464 patients with congestive heart failure treated with ACE inhibitors revealed 221 patients (48%) on aspirin and 243 patients not on aspirin. Although clinical characteristics and therapy were similar, patients taking aspirin experienced lower mortality than patients who did not (24% vs. 34%; p = 0.001). After adjustment, treatment with aspirin was still associated with lower mortality (RR = 0.70; 95% CI = 0.49 to 0.99). CONCLUSIONS: Among coronary artery disease patients with and without heart failure who are treated with ACE inhibitors, the use of aspirin was associated with lower mortality than treatment without aspirin. Our findings contradict the claim that aspirin attenuates the beneficial effect of ACE inhibitors and supports its use in patients with coronary artery disease treated with ACE inhibitors. |
| | |
Authors:
|
J Leor; H Reicher-Reiss; U Goldbourt; V Boyko; S Gottlieb; A Battler; S Behar |
Related Documents
:
|
14636904 - Relation of hemoglobin a1c to rate of major adverse cardiac events in nondiabetic patie... 12588224 - Clinical risk factors for mortality in patients with neurofibromatosis 1: a cohort stud... 20613714 - Fgf-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. 912844 - Prognostic efficacy of early clinical categorization of myocardial infarction patients. 4093574 - Treatment of smoke inhalation by hyperbaric oxygen. 16451284 - Do patients prescribed short-burst oxygen therapy meet criteria for ambulatory oxygen? |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 33 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 1999 Jun |
Date Detail:
|
Created Date: 1999-06-22 Completed Date: 1999-06-22 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1920-5 Citation Subset: AIM; IM |
Affiliation:
|
Cardiology Department, Soroka Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel. jleor@bgumail.bgu.ac.il |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin-Converting Enzyme Inhibitors
/
therapeutic use* Aspirin / therapeutic use* Captopril / therapeutic use Coronary Disease / drug therapy, mortality* Cross-Over Studies Drug Interactions Drug Therapy, Combination Enalapril / therapeutic use Female Heart Failure / drug therapy, mortality Humans Israel / epidemiology Male Middle Aged Platelet Aggregation Inhibitors / therapeutic use* Registries / statistics & numerical data Risk Factors Survival Rate |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 62571-86-2/Captopril; 75847-73-3/Enalapril |
| Comments/Corrections | |
Comment In:
|
J Am Coll Cardiol. 2000 Mar 1;35(3):817-9
[PMID:
10716490
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Increased winter mortality from acute myocardial infarction and stroke: the effect of age.
Next Document: Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricula...